Sign in

    John Penny

    Managing Director and Senior Equity Analyst at Canaccord Genuity

    John Penny is a Managing Director and Senior Equity Analyst at Canaccord Genuity, specializing in coverage of innovative healthcare companies such as Fractyl Health. He is recognized for providing buy-side recommendations backed by rigorous analysis of clinical trial data and market penetration potential, with recent success projections including a $400 million sales target for Fractyl Health's lead product. Penny's career spans over 25 years on both the buy and sell sides of the industry, having previously held analyst roles at major firms before joining Canaccord Genuity following its merger with Genuity Capital Markets. He holds multiple securities licenses and maintains active FINRA registration, underscoring his expertise and regulatory compliance in equity research.

    John Penny's questions to Progyny (PGNY) leadership

    John Penny's questions to Progyny (PGNY) leadership • Q4 2024

    Question

    John Penny, on for Richard Close, questioned the drivers behind the lower female utilization rate guidance for 2025 and asked for more detail on the planned investments to integrate the recent Benefit Bump acquisition.

    Answer

    CFO Mark Livingston explained the lower utilization guidance reflects a dilutive effect from a mature, high-utilization client being replaced by new clients who typically have lower utilization in their first year. CEO Peter Anevski added that investments are focused on creating a seamless, integrated member experience across all assets, including Benefit Bump, global offerings, and the core platform.

    Ask Fintool Equity Research AI